sNDA Submitted to FDA for Approval of Venetoclax/Obinutuzumab in Treatment Naive CLL - Targeted Oncology https://t.co/f9Mk13DeQL
— IDRO (@IDROOhio) March 8, 2019
from Twitter https://twitter.com/IDROOhio
March 08, 2019 at 01:52AM
Friday, March 8, 2019
sNDA Submitted to FDA for Approval of Venetoclax/Obinutuzumab in Treatment Naive CLL - Targeted Oncology https://t.co/f9Mk13DeQL
from Twitter https://twitter.com/IDROOhio
March 08, 2019 at 01:52AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment